JP2022514393A - ナチュラルキラー細胞に分化させるための培地および方法 - Google Patents

ナチュラルキラー細胞に分化させるための培地および方法 Download PDF

Info

Publication number
JP2022514393A
JP2022514393A JP2021535699A JP2021535699A JP2022514393A JP 2022514393 A JP2022514393 A JP 2022514393A JP 2021535699 A JP2021535699 A JP 2021535699A JP 2021535699 A JP2021535699 A JP 2021535699A JP 2022514393 A JP2022514393 A JP 2022514393A
Authority
JP
Japan
Prior art keywords
cells
cell
population
cell differentiation
progenitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021535699A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022514393A5 (enExample
Inventor
ヌーシン タバタバエイ－ザバレ
アルベルトゥス ヴェルネルス ウォヌム
Original Assignee
ステムセル テクノロジーズ カナダ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ステムセル テクノロジーズ カナダ インコーポレイテッド filed Critical ステムセル テクノロジーズ カナダ インコーポレイテッド
Publication of JP2022514393A publication Critical patent/JP2022514393A/ja
Publication of JP2022514393A5 publication Critical patent/JP2022514393A5/ja
Priority to JP2024194867A priority Critical patent/JP2025024025A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2303—Interleukin-3 (IL-3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2307—Interleukin-7 (IL-7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2312—Interleukin-12 (IL-12)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2321—Interleukin-21 (IL-21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/14—Coculture with; Conditioned medium produced by hepatocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
JP2021535699A 2018-12-21 2019-12-20 ナチュラルキラー細胞に分化させるための培地および方法 Pending JP2022514393A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024194867A JP2025024025A (ja) 2018-12-21 2024-11-07 ナチュラルキラー細胞に分化させるための培地および方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862783341P 2018-12-21 2018-12-21
US62/783,341 2018-12-21
PCT/CA2019/051875 WO2020124256A1 (en) 2018-12-21 2019-12-20 Media and methods for differentiating natural killer cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024194867A Division JP2025024025A (ja) 2018-12-21 2024-11-07 ナチュラルキラー細胞に分化させるための培地および方法

Publications (2)

Publication Number Publication Date
JP2022514393A true JP2022514393A (ja) 2022-02-10
JP2022514393A5 JP2022514393A5 (enExample) 2022-12-19

Family

ID=71102436

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021535699A Pending JP2022514393A (ja) 2018-12-21 2019-12-20 ナチュラルキラー細胞に分化させるための培地および方法
JP2024194867A Pending JP2025024025A (ja) 2018-12-21 2024-11-07 ナチュラルキラー細胞に分化させるための培地および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024194867A Pending JP2025024025A (ja) 2018-12-21 2024-11-07 ナチュラルキラー細胞に分化させるための培地および方法

Country Status (8)

Country Link
US (1) US20220056412A1 (enExample)
EP (1) EP3898951A4 (enExample)
JP (2) JP2022514393A (enExample)
KR (1) KR102932302B1 (enExample)
CN (1) CN113383070A (enExample)
CA (1) CA3124266A1 (enExample)
SG (1) SG11202106565WA (enExample)
WO (1) WO2020124256A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113337466B (zh) * 2021-07-13 2023-03-24 杭州原生生物科技有限公司 一种无血清nk分化培养基及其制备方法
CN113789299B (zh) * 2021-10-18 2023-03-24 新鲁细胞生物科技(海南)有限公司 一种脐血nk细胞的体外增殖培养基、体外培养试剂盒和体外培养方法
CN119137261A (zh) 2021-12-17 2024-12-13 优莫佳生物制药股份有限公司 细胞毒性先天淋巴样细胞及其用途
KR20250022800A (ko) 2022-06-10 2025-02-17 우모자 바이오파마 인코포레이티드 조작된 줄기 세포 및 그의 용도
US20260176585A1 (en) * 2022-11-07 2026-06-25 Maru Therapeutics Co., Ltd. Cultivation method for enhancing differentiation efficiency and functionality of nk cells
WO2024101863A1 (ko) * 2022-11-07 2024-05-16 마루테라퓨틱스 주식회사 줄기세포 기원 및 발현 마커에 따른 nk 세포 분화 효율 증진 방법
IL328711A (en) 2023-12-13 2026-07-01 Umoja Biopharma Inc Myeloid cells derived from engineered induced stem cells and methods for differentiating and using them
WO2026123001A2 (en) 2024-12-06 2026-06-11 Umoja Biopharma, Inc. Lineage-loci engineered cell therapy and related methods of producing and using same
WO2026123000A2 (en) 2024-12-06 2026-06-11 Umoja Biopharma, Inc. Cytokine armored engineered innate lymphoid cells and related methods

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017173551A1 (en) * 2016-04-08 2017-10-12 The Governing Council Of The University Of Toronto Method for generating progenitor t cells from stem and/or progenitor cells and use of same

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090123442A1 (en) * 2007-11-09 2009-05-14 Avaris Ab Expanded nk cells
WO2013119118A1 (en) * 2012-02-08 2013-08-15 Ipd-Therapeutics B.V. Ex vivo nk cell differentiation from cd34+ hematopoietic cells
KR20230146101A (ko) * 2014-12-31 2023-10-18 안트로제네시스 코포레이션 천연 킬러 세포 및 그의 용도
WO2016191879A1 (en) * 2015-06-05 2016-12-08 Héma-Québec Methods for culturing and/or differentiating hematopoietic stem cells into progenitors and uses thereof
US20190209618A1 (en) * 2016-04-26 2019-07-11 Mcmaster University Methods and compositions for expansion of hematopoietic stem and/or progenitor cells employing a cytochrome p450 1b1 (cyp1b1) inhibitor or a musashi-2 (msi2) activator
GB201706544D0 (en) * 2017-04-25 2017-06-07 Plasticell Ltd Method

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017173551A1 (en) * 2016-04-08 2017-10-12 The Governing Council Of The University Of Toronto Method for generating progenitor t cells from stem and/or progenitor cells and use of same

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
MESQUITTA, WT. ET AL.: "Pyrimido-indole derivative, UM171 expands distinct types of myeloid and lymphoid progenitors from hu", BLOOD, vol. 132(1), JPN6023041631, 29 November 2018 (2018-11-29), pages 3835, ISSN: 0005528537 *
MESQUITTA, WT. ET AL.: "Pyrimido-indole derivative, UM171 promotes differentiation and expansion of myeloid progenitors and", EXPERIMENTAL HEMATOLOGY, vol. 64(22), JPN6023041630, August 2018 (2018-08-01), pages 87, ISSN: 0005528536 *
TABATABAEI-ZAVAREH, N ET AL.: "Differentiation of hematopoietic stem and progenitor cells to NK cells in a stroma-free, serum-free", J IMMUNOL, vol. 200(1), JPN6023041632, 1 May 2018 (2018-05-01), pages 103 - 4, ISSN: 0005528538 *

Also Published As

Publication number Publication date
EP3898951A4 (en) 2022-08-31
SG11202106565WA (en) 2021-07-29
WO2020124256A1 (en) 2020-06-25
CA3124266A1 (en) 2020-06-25
JP2025024025A (ja) 2025-02-19
KR102932302B1 (ko) 2026-02-27
KR20210114422A (ko) 2021-09-23
US20220056412A1 (en) 2022-02-24
CN113383070A (zh) 2021-09-10
EP3898951A1 (en) 2021-10-27

Similar Documents

Publication Publication Date Title
KR102932302B1 (ko) 자연살해세포의 분화를 위한 배지 및 방법
US20210395683A1 (en) Methods of producing t memory stem cell populations
JP3160600B2 (ja) ヒト造血幹細胞
McGuckin et al. Production of stem cells with embryonic characteristics from human umbilical cord blood
Lupo et al. Differentiation of natural killer cells from induced pluripotent stem cells under defined, serum-and feeder-free conditions
KR20180066263A (ko) 조혈 세포 분화를 유도하기 위한 방법 및 조성물
McGuckin et al. Potential for access to embryonic‐like cells from human umbilical cord blood
JP2022172252A (ja) 造血移植片の改善方法
US20120114614A1 (en) Methods and compositions for long term hematopoietic repopulation
US20240218328A1 (en) Compositions and methods for differentiating and expanding b lineage cells
EP1127107B1 (en) Methods for the production of tcr gamma delta t cells
US20230257707A1 (en) Systems and methods for differentiating hematopoietic cells
EP0711111A1 (en) Novel stem cell marker
US20240240144A1 (en) Generating t cell precursors via agonizing tumor necrosis factor receptor 2
JP2024533065A (ja) リンパ球効力アッセイ
US20240150713A1 (en) Method for Producing Human Chimeric Antigen Receptor T-Cell Population Enriched with Stem Cell-like Memory T-Cells
WO2025210582A1 (en) Materials, methods and systems for cellular redifferentiation and expansion
WO2025073655A2 (en) Use of artificial marrow organoid for generating nk cells and myeloid cells
US20080112933A1 (en) Methods and Compositions for Increasing Stem Cell Homing Using Gas Activators
CN117916388A (zh) 淋巴细胞效力测定

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210820

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221209

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221209

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231010

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240109

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240307

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20240329

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240708

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241209

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241220

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20241224

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20260703